Publication Date
| In 2025 | 0 |
| Since 2024 | 0 |
| Since 2021 (last 5 years) | 0 |
| Since 2016 (last 10 years) | 0 |
| Since 2006 (last 20 years) | 1 |
Descriptor
| Adolescents | 1 |
| Antisocial Behavior | 1 |
| Autism | 1 |
| Check Lists | 1 |
| Children | 1 |
| Drug Therapy | 1 |
| Metabolism | 1 |
| Outcomes of Treatment | 1 |
| Pathology | 1 |
| Pervasive Developmental… | 1 |
| Physiology | 1 |
| More ▼ | |
Source
| Journal of Autism and… | 1 |
Author
| Early, Maureen C. | 1 |
| Erickson, Craig A. | 1 |
| Mathieu-Frasier, Lauren | 1 |
| McDougle, Christopher J. | 1 |
| Patrick, Vanessa | 1 |
| Stiegelmeyer, Elizabeth | 1 |
| Wink, Logan K. | 1 |
Publication Type
| Journal Articles | 1 |
| Reports - Research | 1 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
| Aberrant Behavior Checklist | 1 |
What Works Clearinghouse Rating
Peer reviewed
Direct linkErickson, Craig A.; Wink, Logan K.; Early, Maureen C.; Stiegelmeyer, Elizabeth; Mathieu-Frasier, Lauren; Patrick, Vanessa; McDougle, Christopher J. – Journal of Autism and Developmental Disorders, 2014
Rationale: An excitatory/inhibitory (E:I) imbalance marked by enhanced glutamate and deficient gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of autism spectrum disorders (ASD). Objectives: We report on the first single-blind placebo lead-in trial of acamprosate, a drug with putative mechanisms restoring E:I…
Descriptors: Autism, Pervasive Developmental Disorders, Drug Therapy, Metabolism
